Cutler Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Hold |
0
| – | – | – | 1471 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 1771 |
|
|
2022
Q3 | – | Sell |
-1,443
| Closed | -$15K | – | 1931 |
|
|
2022
Q2 | $15K | Sell |
1,443
-7,047
| -83% | -$73.3K | ﹤0.01% | 1261 |
|
|
2022
Q1 | $138K | Buy |
8,490
+2,274
| +37% | +$37K | 0.01% | 705 |
|
|
2021
Q4 | $86K | Sell |
6,216
-16,844
| -73% | -$233K | ﹤0.01% | 985 |
|
|
2021
Q3 | $331K | Buy |
23,060
+15,160
| +192% | +$218K | 0.01% | 531 |
|
|
2021
Q2 | $124K | Buy |
+7,900
| New | +$124K | 0.01% | 906 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 1715 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 1572 |
|
|
2019
Q3 | – | Sell |
-2,400
| Closed | -$9K | – | 1507 |
|
|
2019
Q2 | $9K | Sell |
2,400
-1,900
| -44% | -$7.13K | ﹤0.01% | 1301 |
|
|
2019
Q1 | $35K | Buy |
4,300
+4,100
| +2,050% | +$33.4K | ﹤0.01% | 920 |
|
|
2018
Q4 | $1K | Hold |
200
| – | – | ﹤0.01% | 1514 |
|
|
2018
Q3 | $1K | Sell |
200
-500
| -71% | -$2.5K | ﹤0.01% | 1521 |
|
|
2018
Q2 | $4K | Buy |
700
+500
| +250% | +$2.86K | ﹤0.01% | 1458 |
|
|
2018
Q1 | $0 | Buy |
200
+100
| +100% | – | ﹤0.01% | 1823 |
|
|
2017
Q4 | $0 | Sell |
100
-8,332
| -99% | – | ﹤0.01% | 2127 |
|
|
2017
Q3 | $44K | Sell |
8,432
-3,560
| -30% | -$18.6K | ﹤0.01% | 1310 |
|
|
2017
Q2 | $66K | Buy |
11,992
+1,420
| +13% | +$7.82K | ﹤0.01% | 1345 |
|
|
2017
Q1 | $88K | Sell |
10,572
-6,328
| -37% | -$52.7K | ﹤0.01% | 1206 |
|
|
2016
Q4 | $106K | Buy |
16,900
+1,500
| +10% | +$9.41K | ﹤0.01% | 1166 |
|
|
2016
Q3 | $67K | Sell |
15,400
-22,026
| -59% | -$95.8K | ﹤0.01% | 1282 |
|
|
2016
Q2 | $106K | Sell |
37,426
-600
| -2% | -$1.7K | 0.01% | 983 |
|
|
2016
Q1 | $107K | Buy |
38,026
+18,400
| +94% | +$51.8K | 0.01% | 902 |
|
|
2015
Q4 | $202K | Buy |
+19,626
| New | +$202K | 0.01% | 705 |
|